Navigation Links
Expert in IVD Software joins Visiopharm’s Board of Directors

Hørsholm, Denmark (PRWEB) January 03, 2013

Visiopharm a leader of Quantitative Digital Pathology solutions announced today that Dr. Henrik Stender will join Visiopharm’s Board of Directors.

Dr. Henrik Stender is co-founder of AdvanDx, where he was the Vice President of Research & Development. While with AdvanDx, he spearheaded the development of their PNA FISH technology; including clinical and regulatory activities for in-vitro diagnostic (IVD) use in Europe and in the United States. Today, as owner of Stender Diagnostics, Dr. Stender uses an ’IVD Factory’ concept to streamline the development process towards high quality products in compliance with quality system requirements (QSR) for regulatory approvals. Prior to AdvanDx, Henrik was at Applied Biosystems, Boston Probes, and Dako, where he built a deep and broad knowledge about medical devices and in-vitro diagnostics.

“I am very excited about joining Visiopharm, and see tremendous potential for their diagnostic solutions. Visiopharm already has a strong portfolio of algorithms for nuclear, membrane, and gene-probe analysis, which is currently under clinical validation and subsequent deployment at several hospitals. Still, there is a strong focus on developing and validating novel technology in software modules that truly addresses the demand for doing things better, faster, and cheaper. I believe this will be part of defining the future of Digital Pathology”, says Dr. Henrik Stender.

Michael Grunkin, CEO at Visiopharm stated “In-vitro diagnostics is a key business area for Visiopharm. We have an exciting development pipeline of IVD algorithms for the breast tumor panel, and this will set the foundation for the development of several other tumor panels. Dr. Stender is an important addition to our Board of Directors. His extensive knowledge and experience in the development of IVD products will be a great contribution to Visiopharm."

Johan Doré, CTO at Visiopharm adds, “We are seeing some interesting changes in Scandinavia these years, when it comes to adoption of Digital Pathology. We are collaborating with several hospitals in moving Digital Pathology into the clinic, and we have a very strong clinical network for validation though our close collaboration with the NordiQC. With his experience, Henrik is helping us optimizing our development work and clinical network in a regulatory context.”

Visiopharm recently introduced the HER2-CONNECT algorithm as their first CE-IVD cleared module and they are scheduled to launch a full CE-IVD tumor panel in 2013.

About Visiopharm

Over the past 10 years, Visiopharm image analysis and stereology software has become the preferred Quantitative Digital Pathology solution for leading biopharmaceutical companies, clinical researchers, and academic researchers all over the world. Visiopharm has more than 350 deployed systems worldwide and a large network of distribution and support partners, and is featured in over 400 scientific publications.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Nutrisystem Announces Latest Weight Loss Success Story: Long Beach Husband and Wife Drop a Combined Total of 46 Pounds; Plus, Expert Dieting Tips for Couples
2. Kettlebell Expert Lorna Kleidman Responds to the Rise in Fitness Parks throughout Major Cities
3. Fitness Expert Lorna Kleidman Comments on Article Concerning Weight Loss as a New Year’s Resolution
4. Whats Best for Kids Eye Health? Experts Give Insight
5. Boughs of Christmas Trees Hold Many Insects, Bug Expert Says
6. Its OK for Kids to Keep Believing in Santa, Expert Says
7. Stakeholder Communities in China and Korea – by Heartbeat Experts
8. Grief Expert Says "We Don't Die" and Offers Free Aid to Mourners
9. Aspergers, Autism Not Linked to Violence: Experts
10. Banning Vaccine Preservative Would Hurt Kids in Poor Nations: Experts
11. GLOBODOX (Enterprise Document Management Software) Launches Contest for Legal Experts to Define Technology Challenges Expected in 2013
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: